How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings data on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The business earned $76.20 million during the quarter, compared to analyst estimates of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 16.74% and a net margin of 12.70%. During the same period in the prior year, the company posted $0.19 EPS.

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com . Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Micron Technology (MU) , Pfizer (PFE) , AT&T (T) , Gilead Sciences (GILD) , Amgen (AMGN) , Alibaba Group (BABA) and Tesla (TSLA) .

Does Meridian Bioscience have any subsidiaries?

The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience. Read More

NASDAQ:VIVO

Meridian Bioscience (VIVO) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free VIVO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $33.97
▼
$33.97
50-Day Range: $33.00
▼
$33.97
52-Week Range: $20.35
▼
$34.38

Volume: N/A
Average Volume: 973,737 shs
Market Capitalization: $1.50 billion

P/E Ratio: 35.02
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Meridian Bioscience alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Meridian Bioscience Stock (NASDAQ:VIVO)

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

VIVO Stock News Headlines

February 8, 2024 | health.usnews.com

Meridian Meadows Transitional Care

November 28, 2023 | benzinga.com

Meridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to Sustainability

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

July 25, 2023 | finance.yahoo.com

Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex

May 17, 2023 | marketwatch.com

Rapid Testing Kits Market Size Opportunities, Top Countries Data, Future Trends and Share Forecast 2028

April 27, 2023 | marketwatch.com

Rapid Testing Kits Market Size with Growth Opportunities, Top Countries Data, Future Trends and Share with Revenue Forecast 2028

April 19, 2023 | thestreet.com

Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)

April 19, 2023 | markets.businessinsider.com

Meridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 6, 2023 | bizjournals.com

Former executives at Meridian Bioscience subsidiary facing federal charges

April 5, 2023 | markets.businessinsider.com

Meridian Bioscience Comments on DOJ Announcement Regarding Former Executives of Magellan Diagnostics

March 30, 2023 | thestreet.com

Meridian Bioscience Stock Hits New 52-Week Low (VIVO)

March 26, 2023 | thestreet.com

Meridian Bioscience Stock Hits New 52-Week High (VIVO)

March 23, 2023 | usnews.com

Phoenix Union Bioscience High School

March 20, 2023 | marketwatch.com

Global "Diagnostics PCR Market" 2023: On-going Trends and Growth Insights by 2027

February 1, 2023 | finanznachrichten.de

Meridian Bioscience, Inc.: SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

February 1, 2023 | finance.yahoo.com

Meridian Bioscience finalizes $1.53B sale to South Korean-based firms

January 31, 2023 | finance.yahoo.com

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

December 29, 2022 | benzinga.com

Meridian Bioscience's Return On Capital Employed Overview

December 13, 2022 | seekingalpha.com

Meridian Biosciences: Why I Moved On But May Go Back In

December 12, 2022 | finance.yahoo.com

Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

December 12, 2022 | finance.yahoo.com

Meridian Bioscience sets closing date for $1.53 billion deal

November 22, 2022 | seekingalpha.com

Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67M

November 22, 2022 | finance.yahoo.com

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

November 17, 2022 | finance.yahoo.com

BellRing Brands (BRBR) Beats Q4 Earnings Estimates

October 15, 2022 | uk.finance.yahoo.com

Meridian Bioscience, Inc. (VIVO)

September 28, 2022 | msn.com

Vivo X Fold Plus launched: Check price, specifications and other details

See More Headlines

Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/19/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: Health Care Supplies
Current Symbol: NASDAQ:VIVO
CUSIP: 58958410
CIK: 794172
Web: www.meridianbioscience.com
Phone: (513) 271-3700
Fax: 513-271-3762
Employees: 702
Year Founded: 1977

Profitability

EPS (Most Recent Fiscal Year): $0.97
Trailing P/E Ratio: 35.02
Forward P/E Ratio: 40.93
P/E Growth: N/A
Net Income: $42.46 million
Net Margins: 12.70%
Pretax Margin: 16.31%
Return on Equity: 16.74%
Return on Assets: 13.09%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 3.63
Quick Ratio: 2.46

Sales & Book Value

Annual Sales: $333.02 million
Price / Sales: 4.49
Cash Flow: $1.78 per share
Price / Cash Flow: 19.13
Book Value: $8.41 per share
Price / Book: 4.04

Miscellaneous

Outstanding Shares: 44,010,000
Free Float: 42,996,000
Market Cap: $1.50 billion
Optionable: Optionable
Beta: 0.23

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

John Patrick Kenny
Chief Executive Officer & Executive Director
Andrew S. Kitzmiller
Chief Financial Officer & Executive Vice President
Julie Smith
Chief Accounting Officer, Senior VP & Controller
Emerson C. Moser
Senior Vice President & General Counsel
Lourdes Weltzien
Executive Vice President-Life Science

Key Competitors

View All Competitors

VIVO Stock Analysis - Frequently Asked Questions

How were Meridian Bioscience's earnings last quarter?: Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings data on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The business earned $76.20 million during the quarter, compared to analyst estimates of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 16.74% and a net margin of 12.70%. During the same period in the prior year, the company posted $0.19 EPS.
What is Jack Kenny's approval rating as Meridian Bioscience's CEO?: 7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Meridian Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).
Does Meridian Bioscience have any subsidiaries?: The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.
Read More

This page (NASDAQ:VIVO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Meridian Bioscience (VIVO) Stock Price, News & Analysis

About Meridian Bioscience Stock (NASDAQ:VIVO)

VIVO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

VIVO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info